全球尋常型天皰瘡市場規模、份額和趨勢分析報告—產業概覽和 2032 年預測

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Pharmaceutical Global Pemphigus Vulgaris Market
请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

全球尋常型天皰瘡市場規模、份額和趨勢分析報告—產業概覽和 2032 年預測

  • Pharmaceutical
  • Published Report
  • Jul 2023
  • Global
  • 350 页面
  • 桌子數： 576
  • 图号： 40
立即购买 立即购买 索取樣品 索取樣品
Nucleus Nucleus

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Global Pemphigus Vulgaris Market

市场规模（十亿美元）

CAGR :  % Diagram

Chart Image USD 419.49 Billion USD 809.71 Billion 2024 2032
Diagram Forecast Period
 2025 –2032
Diagram Market Size (Base Year)
 USD 419.49 Billion
Diagram Market Size (Forecast Year)
 USD 809.71 Billion
Diagram CAGR
 %
Diagram Major Markets Players
  • Merck & Co. Inc.
  • Sanofi
  • Regeneron Pharmaceuticals Inc.
  • Johnson & Johnson Services Inc.
  • AstraZeneca

全球尋常型天皰瘡市場細分，按診斷和治療（診斷和治療）、人群類型（兒科、成人和老年人）、最終用戶（醫院、專科診所、研究機構等）、分銷渠道（醫院藥房、零售藥房和網上藥房） - 行業趨勢和預測至 2032 年

尋常型天皰瘡市場

尋常型天皰瘡市場規模

  • 2024 年全球尋常型天皰瘡市場規模為4.1949 億美元 ，預計 到 2032 年將達到 8.0971 億美元，預測期內 複合年增長率為 8.7%
  • 市場成長主要得益於尋常型天皰瘡盛行率的上升、人們對自體免疫性皮膚病認識的提高、診斷技術的進步以及對有效治療方案研發的投資不斷增加
  • 此外，由於醫療基礎設施的改善、患者獲得先進療法的機會增加、政府的支持性舉措以及對生物製劑和針對性治療的日益關注，預計市場將繼續擴張，以更有效地管理尋常型天皰瘡

尋常型天皰瘡市場尋常型天皰瘡市場

尋常型天皰瘡市場分析

  • 市場受到尋常型天皰瘡發病率上升、對自體免疫疾病認識的提高以及生物療法的進步的推動，導致全球對有效治療方案和改善患者預後的需求增加
  • 影響市場成長的關鍵因素包括擴大醫療基礎設施、增加醫療支出、政府對罕見疾病研究的支持，以及正在進行的針對尋常型天皰瘡管理的新療法的臨床試驗
  • 預計到 2025 年，北美將佔據尋常型天皰瘡市場的主導地位，收入份額將達到 45.93%，這得益於先進的醫療基礎設施、患者認知度高、研發活動強勁、生物療法的廣泛普及以及政府大力推廣罕見疾病治療的舉措
  • 預計亞太地區將成為預測期內尋常型天皰瘡市場成長最快的地區，這得益於醫療保健投資的增加、患者人數的增加、意識的提高、診斷設施的改善以及新興經濟體獲得先進治療的機會的擴大
  • 預計到 2025 年，治療領域將佔據尋常型天皰瘡市場的主導地位，佔比 66.33%，這主要得益於生物療法需求的不斷增長、自身免疫性疾病患病率的上升、治療方案的進步以及患者對有效標靶治療的偏好日益增強

報告範圍和尋常型天皰瘡市場細分

屬性

尋常型天皰瘡關鍵市場洞察

涵蓋的領域
  • 按診斷和治療：診斷和治療
  • 依人口類型：兒科、成人和老年人
  • 依最終使用者：醫院、專科診所、研究機構等
  • 按分銷管道：醫院藥房、零售藥房和線上藥房

覆蓋國家

亞太

  • 中國
  • 印度
  • 韓國
  • 馬來西亞
  • 日本
  • 澳洲
  • 新加坡
  • 泰國
  • 印尼
  • 紐西蘭
  • 台灣
  • 菲律賓
  • 香港
  • 亞太其他地區

北美洲

  • 我們
  • 加拿大
  • 墨西哥

歐洲

  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 瑞士
  • 火雞
  • 俄羅斯
  • 比利時
  • 荷蘭
  • 丹麥
  • 挪威
  • 芬蘭
  • 波蘭
  • 瑞典
  • 歐洲其他地區

南美洲

  • 巴西
  •  阿根廷
  •  哥倫比亞
  •  秘魯
  •  烏拉圭
  •  厄瓜多
  •  巴拉圭
  •  委內瑞拉
  •  玻利維亞
  •  南美洲其他地區

中東和非洲

  • 沙烏地阿拉伯 
  •  埃及
  •  阿聯酋
  •  南非 
  •  以色列
  • 巴林
  • 科威特
  • 阿曼
  • 卡達
  • 中東和非洲其他地區

主要市場參與者
  • 默克公司（美國）
  • 賽諾菲（法國）
  • 再生元製藥公司（美國）
  • 強生服務公司（美國）
  • 阿斯特捷利康（英國）
  • GRIFOLS SA（西班牙）
  • Zydus集團（印度）
  • F. Hoffmann-La Roche Ltd（瑞士）
  • 葛蘭素史克公司（英國）
  • 勃林格殷格翰國際有限公司（德國）
  • Celltrion（韓國）
  • 禮來（美國）
  • 輝瑞公司（美國）
  • Abbvie Inc.（美國）
  • 費森尤斯卡比股份公司（德國）
  • Rakshit Drugs Private Limited（印度）
  • 安進公司（美國）
  • 諾華公司（瑞士）
  • 梯瓦製藥工業股份有限公司（以色列）
  • Artiva Biotherapeutics, Inc.（美國）
  • Cabaletta Bio Inc.（美國）
  • Incyte（美國）
  • CSL（澳洲）
  • 巴克斯特（美國）
  • Accord Healthcare（英國）
  • 大雄製藥有限公司（韓國）
  • SUNPHARMA.NS（印度）
  • OCTAPHARMA AG（瑞士）
  • Cipla Health Ltd（印度）
  • BioXpress Therapeutics SA（瑞士）

市場機會
  • 個人化醫療需求日益增長
  • 增加醫療設施

加值資料資訊集

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深度專家分析、患者流行病學、管道分析、定價分析和監管框架。

尋常型天皰瘡市場趨勢

“自體免疫疾病盛行率上升”

  • 自體免疫疾病發生率的不斷上升正在擴大患者群體，推動對診斷、治療和醫療保健服務的需求增加，從而顯著推動全球市場的成長
  • 市場參與者正在大力投資研發，以創造創新的生物製劑和標靶治療，應對日益加重的自體免疫疾病負擔
  • 意識的提高和診斷能力的提高正在促進早期發現，從而增加治療的​​採用並擴大整體市場規模
  • 不斷擴大的自體免疫疾病市場吸引了製藥公司和政府的大量投資，支持基礎設施建設和新產品的推出，從而增強市場競爭力
  • 新興經濟體患病率的不斷上升帶來了新的成長機會，透過改善這些地區的醫療保健服務以及增加醫療保健支出，推動了市場擴張

尋常型天皰瘡市場動態

司機

“尋常型天皰瘡的新興治療選擇”

  • 傳統的皮質類固醇療法雖然有效，但伴隨顯著的副作用和長期健康風險。這催生了對更安全、更有針對性的替代療法的強烈需求。生物療法，尤其是抗CD20單株抗體（例如利妥昔單抗），已顯示出巨大的潛力，因為它可以提高緩解率並減少對類固醇的需求。
  • 例如，根據2022年發表在《醫學前沿》上的一篇文章，免疫療法已顯示出預防或治療疾病的潛力。研究表明，T細胞在天皰瘡中發揮重要作用，並且Dsg3特異性CD4+T細胞的功能已在動物模型中透過誘導界面性皮膚炎和真性紅血球增多症（PV）的表型得到完美驗證。
  • 調節性T細胞（Treg）缺陷也可能透過調節抗Dsg3自體抗體的產生而導致天皰瘡的發生。研究表明，體液自體免疫的主要原因是自身反應性T細胞和B細胞的相互作用。因此，與天皰瘡免疫機制相關的T細胞和B細胞免疫軸是天皰瘡患者的主要治療標靶。
  • 此外，新生兒Fc受體（FcRn）抑制劑和布魯頓酪胺酸激酶（BTK）抑制劑等新型候選藥物正在臨床試驗中取得進展，旨在進一步提高療效和患者安全性。這些創新方法正在擴大治療方案庫，並吸引了製藥公司的大量投資。
  • 主要市場的監管審批、疾病認知度的提升以及醫生對生物製劑的接受度的提高，正在進一步加速市場滲透。隨著研究的持續推進，這些新興療法預計將重塑治療格局，並維持長期的市場成長。
  • 在生物製劑和精準醫療的推動下，尋常型天皰瘡的治療模式正經歷一場關鍵性的改變。隨著對更安全、更有效療法的需求不斷增長，全球市場預計將大幅擴張。 FcRn抑制劑和B細胞標靶療法等創新藥物為患者帶來了新的希望，也為製藥公司帶來了新的收入來源。

克制/挑戰

“尋常型天皰瘡藥物審批的嚴格監管指南”

  • 嚴格的監管指南是指全球衛生機構（例如美國FDA、EMA等）為藥物研發、審批和商業化所製定的嚴格標準。對於尋常型天皰瘡(PV)而言，由於疾病的罕見性和治療的複雜性，這些法規至關重要。
  • 例如，2024 年 11 月，牛津大學出版社的一篇文章強調，嚴格的監管指南（例如美國 FDA 和 EMA 制定的指南）確保尋常型天皰瘡療法經過嚴格的臨床試驗，以確認其安全性和有效性
  • 雖然這些措施對患者安全至關重要，但它們可能會延遲新療法的批准和上市。例如，FDA 的 21 CFR 312 法規和 EMA 的人用藥品委員會 (CHMP) 指南要求在新療法獲得批准之前進行廣泛的階段性試驗，這可能會限制患者獲得有希望的療法。這項嚴格的流程雖然具有保護作用，但在此期間可能會限制治療方案的選擇。
  • 嚴格的監管指南對患者安全至關重要，但在全球尋常型天皰瘡市場，它既帶來了挑戰，也帶來了機會。一方面，這些指南確保患者只能獲得安全有效的療法，增強了人們對已獲批准療法的信心。另一方面，冗長的審批流程和高昂的合規成本可能會阻礙創新，並限制市場准入。

尋常型天皰瘡市場

尋常型天皰瘡市場範圍

市場根據診斷和治療、人口類型、最終用戶和分銷管道進行細分。

  • 按診斷和治療

根據診斷和治療，市場細分為診斷和治療。到2025年，治療領域將佔據市場主導地位，市場份額將達到66.33%，這得益於診斷技術的進步、對早期準確檢測的需求不斷增長、人們的認知度不斷提高，以及為有效管理尋常型天皰瘡而越來越多地採用創新診斷工具。

預計治療領域在 2025 年至 2032 年間將實現 9.0% 的最快增長率，這得益於診斷工具的技術進步、尋常型天皰瘡患病率的增加、早期檢測意識的提高、醫療保健基礎設施的不斷發展以及全球範圍內非侵入性和準確診斷方法的廣泛採用。

  • 按人口類型

根據人群類型，市場細分為兒科、成人和老年。預計到2025年，成人市場將佔據最大的市場收入份額，這得益於兒童尋常型天皰瘡診斷率的上升、護理人員認知度的提高、兒科特異性治療的進步、對早期幹預的日益重視，以及發達地區和新興地區兒科人群醫療保健可及性的提高。

The adults segment is expected to witness the fastest CAGR of 9.0% from 2025 to 2032, driven by increasing prevalence of autoimmune disorders in children, rising parental awareness, advancements in child-friendly therapies, improved diagnostic accuracy, and expanding healthcare infrastructure focused on pediatric care across both developed and emerging markets.

  • By End-User

On the basis of end-user, the market is segmented into hospitals, specialty clinics, research institutes and others. The hospitals segment held the largest market revenue share in 2025, driven by advanced healthcare facilities, availability of specialized medical professionals, comprehensive treatment options, higher patient footfall, growing adoption of innovative therapies, and increased government funding supporting hospital infrastructure for managing pemphigus vulgaris effectively.

The hospitals segment is expected to witness the fastest CAGR from 2025 to 2032, favored for its well-equipped infrastructure, availability of multidisciplinary specialists, advanced diagnostic and treatment facilities, increasing patient preference for hospital care, and expanding healthcare investments supporting better management of complex autoimmune conditions like pemphigus.

  • By Distribution Channel

On the basis of distribution channel, the market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy. The hospitals pharmacy segment accounted for the largest market revenue share in 2025, driven by direct access to prescribed medications, strong hospital partnerships, higher patient trust, availability of specialized drugs, streamlined supply chains, and the ability to provide integrated care and counseling for patients with pemphigus vulgaris.

The hospitals pharmacy segment is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing hospital admissions, growing demand for specialized medications, enhanced supply chain efficiency, and rising preference for in-hospital medication dispensing for pemphigus vulgaris patients.

尋常型天皰瘡市場

Pemphigus Vulgaris Market Regional Analysis

  • North America is expected to dominate the pemphigus vulgaris market with a 45.93% revenue share in 2025, supported by advanced healthcare infrastructure, high patient awareness, robust research and development activities, widespread availability of biologic therapies, and strong government initiatives promoting rare disease treatment.
  • North America’s dominance is strengthened by significant healthcare investments, a well-established pharmaceutical industry, and comprehensive insurance coverage, ensuring patient access to cutting-edge pemphigus vulgaris treatments and diagnostics
  • Additionally, active collaborations between government agencies, research institutions, and biotech companies accelerate innovation and approval of novel therapies, further driving market growth in the region

U.S. Pemphigus Vulgaris Market Insight

U.S. is expected to account for the largest market revenue share of 82.78% in the North America region in 2025, attributed to advanced healthcare infrastructure, increasing awareness, rising prevalence of autoimmune disorders, and growing adoption of novel therapies. Additionally, strong government support and ongoing research boosted market growth in the region.

Canada Pemphigus Vulgaris Market Insight

Canada is expected to register the CAGR of 8.2% from 2025 to 2032, driven by increasing investments in biomedical research, rising incidence of pemphigus vulgaris, advanced healthcare facilities, growing patient awareness, and the introduction of innovative treatments. Strong regulatory support further accelerates market expansion in the region.

Europe Pemphigus Vulgaris Market Insight

Europe is expected to account for a substantial market share of 25.18% in 2025 driven by a well-established healthcare system, high awareness of rare autoimmune diseases, increased access to advanced therapies, and strong presence of key pharmaceutical companies. Supportive regulatory policies and rising research initiatives further contributed to the region's significant market position.

Germany Pemphigus Vulgaris Market Insight

The Germany is expected to hold the largest revenue share of 26.12% within Europe region in 2025, fueled by its robust healthcare infrastructure, high diagnosis rates, growing awareness of pemphigus vulgaris, and strong presence of pharmaceutical firms actively involved in autoimmune disease research and treatment development.

U.K. Pemphigus Vulgaris Market Insight

The U.K. market is expected to grow with a CAGR of 8.9% due to rising awareness of pemphigus vulgaris, increasing healthcare spending, early diagnosis initiatives, and adoption of advanced treatment options. Government support and active clinical research further contribute to the expanding market landscape in the country.

Asia-Pacific Pemphigus Vulgaris Market Insight

Asia-Pacific is expected to capture a significant share of the global pemphigus vulgaris market in 2025, driven by a large patient population, improving healthcare infrastructure, rising awareness of autoimmune diseases, and increasing access to advanced therapies. Growing investments in healthcare and supportive government initiatives further fueled regional market growth.

China Pemphigus Vulgaris Market Insight

China is expected to led the Asia-Pacific market in 2025, supported by a large patient base, rapid improvements in healthcare infrastructure, increased government healthcare spending, and rising awareness of rare autoimmune diseases. Additionally, growing clinical research activities and adoption of innovative treatment options significantly contributed to the country’s market leadership.

India Pemphigus Vulgaris Market Insight

由於疾病認知度的提高、醫療支出的增加、診斷能力的提升以及先進療法的普及，印度尋常型天皰瘡市場預計將穩步增長。政府對罕見疾病管理的支持以及對研發的日益重視，正在進一步加速印度市場的擴張。

尋常型天皰瘡市場份額

尋常型天皰瘡市場主要由知名公司主導，包括：

  • 默克公司（美國）
  • 賽諾菲（法國）
  • 再生元製藥公司（美國）
  • 強生服務公司（美國）
  • 阿斯特捷利康（英國）
  • GRIFOLS SA（西班牙）
  • Zydus集團（印度）
  • F. Hoffmann-La Roche Ltd（瑞士）
  • 葛蘭素史克公司（英國）
  • 勃林格殷格翰國際有限公司（德國）
  • Celltrion（韓國）
  • 禮來（美國）
  • 輝瑞公司（美國）
  • Abbvie Inc.（美國）
  • 費森尤斯卡比股份公司（德國）
  • Rakshit Drugs Private Limited（印度）
  • 安進公司（美國）
  • 諾華公司（瑞士）
  • 梯瓦製藥工業股份有限公司（以色列）
  • Artiva Biotherapeutics, Inc.（美國）
  • Cabaletta Bio Inc.（美國）
  • Incyte（美國）
  • CSL（澳洲）
  • 巴克斯特（美國）
  • Accord Healthcare（英國）
  • 大雄製藥有限公司（韓國）
  • SUNPHARMA.NS（印度）
  • OCTAPHARMA AG（瑞士）
  • Cipla Health Ltd（印度）
  • BioXpress Therapeutics SA（瑞士）

尋常型天皰瘡市場

全球尋常型天皰瘡市場的最新發展

  • 2021年9月，3期PEGASUS試驗評估了利扎布替尼在患有中度至重度尋常型天皰瘡或落葉型天皰瘡（一種罕見的自體免疫性皮膚病）的成人患者中的療效。儘管利札布替尼顯示出一致的安全性，且未出現新的問題，但研究並未達到其主要終點或關鍵次要終點。主要目標－在低劑量皮質類固醇治療下於29至37週之間達到完全緩解－與安慰劑組無顯著差異。這是BTK抑制劑治療天皰瘡的首個安慰劑對照試驗，凸顯了治療這種複雜疾病的挑戰。
  • 2025年2月，再生元和賽諾菲向美國FDA提交了一份補充生物製劑許可申請（sBLA），申請Dupixent用於治療成人大皰性類天皰瘡（BP），這是一種罕見的自體免疫性水泡性疾病。該申請基於ADEPT 2/3期臨床試驗的積極數據，該數據表明Dupixent顯著改善了BP患者的病情緩解、降低了病情嚴重程度並減輕了瘙癢症狀。 FDA已接受該申請並進行優先審查，預計於2025年6月20日做出決定。此次合作旨在為BP患者提供新的治療選擇，進一步拓展Dupixent在自體免疫性水皰性疾病中的作用。
  • 2025年3月，再生元公司（Regeneron）繼Dupixent在治療大皰性類天皰瘡（BP）方面取得成功後，進一步拓展了其在尋常型天皰瘡（PV）治療中的潛力研究。 BP和PV都擁有共同的2型發炎機制，這使得Dupixent成為PV治療的有希望的候選藥物。目前正在進行的研究正在評估Dupixent對PV的療效，早期結果顯示其潛在益處。這項探索旨在為PV患者提供新的治療選擇，進一步拓展Dupixent在自體免疫性水皰性疾病的應用。
  • 2025年4月，默克公司宣佈在德拉瓦州威爾明頓破土動工建設一個先進的生物製劑卓越中心，佔地47萬平方英尺，投資額達10億美元。效率
  • 2024年9月，賽諾菲生物製劑Dupixent在治療大皰性類天皰瘡(BP)和尋常型天皰瘡(PV)——這兩種罕見且危及生命的自身免疫性皮膚病——的疾病緩解和症狀方面均顯示出顯著改善。在ADEPT 3期臨床試驗中，使用Dupixent的BP患者獲得持續緩解的比例是使用安慰劑的患者的五倍。該研究達到了其主要終點和所有關鍵次要終點，顯示出強大的類固醇減量效應。 Dupixent有望成為美國和歐盟首個針對BP和PV的標靶治療藥物，目前正在等待監管機構的批准。

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.3 PATENT ANALYSIS

4.3.1 PATIENT FLOW DIAGRAM

4.3.2 KEY PRICING STRATEGIES

4.3.3 FUTURE THERAPIES

4.3.4 KEY PATIENT ENROLLMENT STRATEGIES

4.4 GLOBAL CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET

4.5 SUPPLY CHAIN ECOSYSTEM

4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: GLOBAL PEMPHIGUS VULGARIS MARKET

4.7 EPIDEMIOLOGY: GLOBAL PEMPHIGUS VULGARIS MARKET

4.7.1 INCIDENCE BY GENDER

4.7.2 TREATMENT RATE

4.7.3 MORTALITY RATE

4.7.4 PATIENT TREATMENT SUCCESS RATES

5 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS

6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS

6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS

6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS

6.2 RESTRAINTS

6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL

6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES

6.3 OPPORTUNITIES

6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE

6.3.2 INCREASING HEALTHCARE FACILITIES

6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT

6.4 CHALLENGES

6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS

6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES

7 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT

7.1 OVERVIEW

7.2 TREATMENT

7.3 DIAGNOSIS

8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE

8.1 OVERVIEW

8.2 ADULTS

8.3 GERIATRIC

8.4 PEDIATRIC

9 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALTY CLINICS

9.4 RESEARCH INSTITUTES

9.5 OTHERS

10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITALS PHARMACY

10.3 RETAIL PHARMACY

10.4 ONLINE PHARMACY

11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 CANADA

11.2.3 MEXICO

11.3 EUROPE

11.3.1 GERMANY

11.3.2 U.K.

11.3.3 FRANCE

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 SWITZERLAND

11.3.7 TURKEY

11.3.8 RUSSIA

11.3.9 BELGIUM

11.3.10 NETHERLANDS

11.3.11 DENMARK

11.3.12 NORWAY

11.3.13 FINLAND

11.3.14 POLAND

11.3.15 SWEDEN

11.3.16 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 INDIA

11.4.3 SOUTH KOREA

11.4.4 MALAYSIA

11.4.5 JAPAN

11.4.6 AUSTRALIA

11.4.7 SINGAPORE

11.4.8 THAILAND

11.4.9 INDONESIA

11.4.10 NEW ZEALAND

11.4.11 TAIWAN

11.4.12 PHILIPPINES

11.4.13 HONG KONG

11.4.14 REST OF ASIA-PACIFIC

11.5 SOUTH AMERICA

11.5.1 BRAZIL

11.5.2 ARGENTINA

11.5.3 COLOMBIA

11.5.4 PERU

11.5.5 URUGUAY

11.5.6 ECUADOR

11.5.7 PARAGUAY

11.5.8 VENEZUELA

11.5.9 BOLIVIA

11.5.10 REST OF SOUTH AMERICA

11.6 MIDDLE EAST AND AFRICA

11.6.1 SAUDI ARABIA

11.6.2 EGYPT

11.6.3 U.A.E.

11.6.4 SOUTH AFRICA

11.6.5 ISRAEL

11.6.6 BAHRAIN

11.6.7 KUWAIT

11.6.8 OMAN

11.6.9 QATAR

11.6.10 REST OF MIDDLE EAST AND AFRICA

12 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 MERCK AND CO. INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 SANOFI

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 REGENERON PHARMACEUTICALS INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 JOHNSON & JOHNSON SERVICES, INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 ASTRAZENECA

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 ABBVIE INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 ACCORD HEALTHCARE

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENT

14.8 AMGEN INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 ARTIVA BIOTHERAPEUTICS, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PIPELINE PORTFOLIO

14.9.4 RECENT DEVELOPMENT

14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 BAXTER

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 BIOXPRESS THERAPEUTICS SA

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 CABALETTA BIO INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT

14.14 CIPLA HEALTH LTD

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 CELLTRION

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 CSL

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENT

14.17 DAEWOONG PHARMACEUTICAL CO.,LTD.

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 F. HOFFMANN- LA ROCHE LTD.

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT/NEWS

14.19 FRESENIUS KABI AG

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENT

14.2 GSK PLC

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENT

14.21 GRIFOLS, S.A.

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENT

14.22 INCYTE

14.22.1 COMPANY SNAPSHOT

14.22.2 REVENUE ANALYSIS

14.22.3 PRODUCT PORTFOLIO

14.22.4 RECENT DEVELOPMENT

14.23 NOVARTIS AG

14.23.1 COMPANY SNAPSHOT

14.23.2 REVENUE ANALYSIS

14.23.3 PRODUCT PORTFOLIO

14.23.4 RECENT DEVELOPMENT

14.24 LILLY

14.24.1 COMPANY SNAPSHOT

14.24.2 REVENUE ANALYSIS

14.24.3 PRODUCT PORTFOLIO

14.24.4 RECENT DEVELOPMENT

14.25 OCTAPHARMA AG

14.25.1 COMPANY SNAPSHOT

14.25.2 REVENUE ANALYSIS

14.25.3 PRODUCT PORTFOLIO

14.25.4 RECENT DEVELOPMENT/NEWS

14.26 PFIZER INC.

14.26.1 COMPANY SNAPSHOT

14.26.2 REVENUE ANALYSIS

14.26.3 PRODUCT PORTFOLIO

14.26.4 RECENT DEVELOPMENT

14.27 RAKSHIT DRUGS PVT. LTD

14.27.1 COMPANY SNAPSHOT

14.27.2 PRODUCT PORTFOLIO

14.27.3 RECENT DEVELOPMENT

14.28 SUN PHARMACEUTICALS INDUSTRIES LTD.

14.28.1 COMPANY SNAPSHOT

14.28.2 REVENUE ANALYSIS

14.28.3 PRODUCT PORTFOLIO

14.28.4 RECENT DEVELOPMENT

14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD

14.29.1 COMPANY SNAPSHOT

14.29.2 REVENUE ANALYSIS

14.29.3 PRODUCT PORTFOLIO

14.29.4 RECENT DEVELOPMENT

14.3 ZYDUS GROUP

14.30.1 COMPANY SNAPSHOT

14.30.2 REVENUE ANALYSIS

14.30.3 PRODUCT PORTFOLIO

14.30.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL PEMPHIGUS VULGARIS MARKET

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL PEMPHIGUS VULGARIS MARKET

TABLE 4 SURVIVAL RATES IN PEMPHIGUS VULGARIS

TABLE 5 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 6 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2028-2032 (USD MILLION)

TABLE 7 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 8 GLOBAL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 9 GLOBAL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 10 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 11 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 12 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 13 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 15 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 16 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 17 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 18 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 19 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 20 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 21 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 22 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 23 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 24 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 25 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 26 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 27 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)

TABLE 28 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 29 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 30 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 31 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 32 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 33 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 34 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 35 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 37 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 39 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 40 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 41 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 42 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 43 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 44 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 45 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 47 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 48 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 49 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 50 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 51 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 52 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 53 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 54 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 55 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 57 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 58 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 59 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 60 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 61 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 62 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 63 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 64 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 65 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 67 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 68 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 69 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 70 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 71 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 72 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 73 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 74 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 75 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 76 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 78 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 79 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 80 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 81 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 82 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 83 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 84 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 85 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 86 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 88 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 89 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 90 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 91 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 92 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 93 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 94 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 95 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 96 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 98 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 99 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 100 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 101 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 102 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 103 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 104 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 105 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 106 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 108 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 109 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 110 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 111 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 112 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 113 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 114 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 115 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 116 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 118 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 119 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 120 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 121 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 122 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 123 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 124 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 125 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 126 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 128 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 129 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 130 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 131 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 132 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 133 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 134 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 135 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 136 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 138 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 139 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 140 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 141 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 142 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 143 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 144 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 145 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 146 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 148 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 149 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 150 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 151 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 152 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 153 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 154 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 155 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 156 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 158 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 159 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 160 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 161 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 162 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 163 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 164 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 165 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 166 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 168 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 169 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 170 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 171 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 172 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 173 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 174 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 175 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 176 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 178 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 179 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 180 DENMARK PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 181 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 182 DENMARK STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 183 DENMARK ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 184 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 185 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 186 DENMARK DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 187 DENMARK PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 188 DENMARK PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 189 DENMARK PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 190 NORWAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 191 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 192 NORWAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 193 NORWAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 194 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 195 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 196 NORWAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 197 NORWAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 198 NORWAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 199 NORWAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 200 FINLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 201 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 202 FINLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 203 FINLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 204 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 205 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 206 FINLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 207 FINLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 208 FINLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 209 FINLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 210 POLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 211 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 212 POLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 213 POLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 214 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 215 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 216 POLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 217 POLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 218 POLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 219 POLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 220 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 221 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 222 SWEDEN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 223 SWEDEN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 224 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 225 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 226 SWEDEN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 227 SWEDEN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 228 SWEDEN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 229 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 230 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 231 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 232 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 233 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 234 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 235 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 236 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 237 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 238 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 239 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 240 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 241 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 242 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 243 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 244 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 245 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 246 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 247 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 248 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 249 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 250 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 251 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 252 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 253 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 254 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 255 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 256 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 257 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 258 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 259 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 260 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 261 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 262 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 263 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 264 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 265 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 266 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 267 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 268 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 269 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 270 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 271 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 272 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 273 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 274 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 275 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 276 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 277 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 278 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 279 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 280 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 281 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 282 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 283 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 284 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 285 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 286 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 287 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 288 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 289 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 290 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 291 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 292 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 293 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 294 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 295 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 296 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 297 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 298 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 299 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 300 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 301 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 302 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 303 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 304 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 305 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 306 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 307 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 308 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 309 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 310 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 311 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 312 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 313 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 314 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 315 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 316 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 317 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 318 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 319 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 320 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 321 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 322 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 323 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 324 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 325 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 326 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 327 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 328 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 329 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 330 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 331 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 332 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 333 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 334 NEW ZEALAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 335 NEW ZEALAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 336 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 337 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 338 NEW ZEALAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 339 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 340 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 341 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 342 TAIWAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 343 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 344 TAIWAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 345 TAIWAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 346 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 347 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 348 TAIWAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 349 TAIWAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 350 TAIWAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 351 TAIWAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 352 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 353 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 354 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 355 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 356 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 357 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 358 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 359 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 360 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 361 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 362 HONG KONG PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 363 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 364 HONG KONG STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 365 HONG KONG ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 366 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 367 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 368 HONG KONG DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 369 HONG KONG PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 370 HONG KONG PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 371 HONG KONG PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 372 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 373 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 374 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 375 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 376 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 377 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 378 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 379 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 380 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 381 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 382 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 383 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 384 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 385 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 386 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 387 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 388 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 389 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 390 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 391 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 392 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 393 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 394 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 395 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 396 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 397 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 398 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 399 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 400 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 401 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 402 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 403 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 404 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 405 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 406 COLOMBIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 407 COLOMBIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 408 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 409 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 410 COLOMBIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 411 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 412 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 413 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 414 PERU PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 415 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 416 PERU STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 417 PERU ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 418 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 419 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 420 PERU DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 421 PERU PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 422 PERU PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 423 PERU PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 424 URUGUAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 425 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 426 URUGUAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 427 URUGUAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 428 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 429 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 430 URUGUAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 431 URUGUAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 432 URUGUAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 433 URUGUAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 434 ECUADOR PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 435 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 436 ECUADOR STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 437 ECUADOR ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 438 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 439 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 440 ECUADOR DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 441 ECUADOR PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 442 ECUADOR PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 443 ECUADOR PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 444 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 445 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 446 PARAGUAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 447 PARAGUAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 448 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 449 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 450 PARAGUAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 451 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 452 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 453 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 454 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 455 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 456 VENEZUELA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 457 VENEZUELA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 458 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 459 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 460 VENEZUELA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 461 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 462 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 463 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 464 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 465 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 466 BOLIVIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 467 BOLIVIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 468 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 469 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 470 BOLIVIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 471 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 472 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 473 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 474 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 475 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 476 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 477 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 478 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 479 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 480 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 481 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 482 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 483 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 484 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 485 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 486 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 487 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 488 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 489 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 490 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 491 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 492 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 493 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 494 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 495 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 496 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 497 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 498 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 499 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 500 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 501 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 502 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 503 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 504 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 505 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 506 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 507 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 508 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 509 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 510 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 511 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 512 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 513 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 514 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 515 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 516 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 517 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 518 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 519 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 520 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 521 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 522 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 523 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 524 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 525 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 526 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 527 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 528 ISRAEL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 529 ISRAEL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 530 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 531 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 532 ISRAEL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 533 ISRAEL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 534 ISRAEL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 535 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 536 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 537 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 538 BAHRAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 539 BAHRAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 540 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 541 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 542 BAHRAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 543 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 544 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 545 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 546 KUWAIT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 547 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 548 KUWAIT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 549 KUWAIT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 550 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 551 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 552 KUWAIT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 553 KUWAIT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 554 KUWAIT PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 555 KUWAIT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 556 OMAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 557 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 558 OMAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 559 OMAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 560 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 561 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 562 OMAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 563 OMAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 564 OMAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 565 OMAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 566 QATAR PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

TABLE 567 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 568 QATAR STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 569 QATAR ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 570 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)

TABLE 571 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)

TABLE 572 QATAR DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 573 QATAR PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)

TABLE 574 QATAR PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 575 QATAR PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 576 REST OF MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)

图片列表

FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION

FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: END USER COVERAGE GRID

FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, (2024)

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 15 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARIS IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2025 TO 2032

FIGURE 16 DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2025 AND 2032

FIGURE 17 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 18 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:-

FIGURE 19 DROC ANALYSIS

FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2024

FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD MILLION)

FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)

FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE

FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2024

FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2025-2032 (USD MILLION)

FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2025-2032)

FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2024

FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2025-2032 (USD MILLION)

FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2025-2032)

FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2024)

FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)

FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)

FIGURE 39 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)

FIGURE 40 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 全球尋常型天皰瘡市場細分，按診斷和治療（診斷和治療）、人群類型（兒科、成人和老年人）、最終用戶（醫院、專科診所、研究機構等）、分銷渠道（醫院藥房、零售藥房和網上藥房） - 行業趨勢和預測至 2032 年 进行细分的。
在2024年，全球尋常型天皰瘡市場的规模估计为419.49 USD Billion美元。
全球尋常型天皰瘡市場预计将在2025年至2032年的预测期内以CAGR 8.7%的速度增长。
市场上的主要参与者包括Merck & Co. Inc., Sanofi, Regeneron Pharmaceuticals Inc., Johnson & Johnson Services Inc., AstraZeneca。

浏览相关页面

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future